Literature DB >> 27728807

LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.

Phuong-Hien Nguyen1, Oleg Fedorchenko1, Natascha Rosen1, Maximilian Koch1, Romy Barthel1, Tomasz Winarski1, Alexandra Florin2, F Thomas Wunderlich3, Nina Reinart1, Michael Hallek4.   

Abstract

Survival of chronic lymphocytic leukemia (CLL) cells strictly depends on the support of an appropriate tumor microenvironment. Here, we demonstrate that LYN kinase is essential for CLL progression. Lyn deficiency results in a significantly reduced CLL burden in vivo. Loss of Lyn within leukemic cells reduces B cell receptor (BCR) signaling including BTK phosphorylation, but surprisingly does not affect leukemic cell expansion. Instead, syngeneic CLL transplantation of CLL cells into Lyn- or Btk-deficient recipients results in a strongly delayed leukemic progression and prolonged survival. Moreover, Lyn deficiency in macrophages hinders nursing functions for CLL cells, which is mediated by direct contact rather than secretion of soluble factors. Taken together, LYN and BTK seem essential for the formation of a microenvironment supporting leukemic growth.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27728807     DOI: 10.1016/j.ccell.2016.09.007

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  18 in total

Review 1.  On the architecture of translational research designed to control chronic lymphocytic leukemia.

Authors:  Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Authors:  Adrian Wiestner; Sarah E M Herman; Eman L Dadashian; Erin M McAuley; Delong Liu; Arthur L Shaffer; Ryan M Young; Jessica R Iyer; Michael J Kruhlak; Louis M Staudt
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

3.  Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.

Authors:  Viktoria Kohlhas; Michael Hallek; Phuong-Hien Nguyen
Journal:  Blood Adv       Date:  2020-12-22

Review 4.  Mature lymphoid malignancies: origin, stem cells, and chronicity.

Authors:  Simon Husby; Kirsten Grønbæk
Journal:  Blood Adv       Date:  2017-11-28

Review 5.  Src Family Protein Kinase Controls the Fate of B Cells in Autoimmune Diseases.

Authors:  Xianzheng Zhang; Dan Mei; Lingling Zhang; Wei Wei
Journal:  Inflammation       Date:  2020-10-10       Impact factor: 4.092

6.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 7.  Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Authors:  Christopher Pleyer; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-05-15

Review 8.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Authors:  Jan A Burger; Adrian Wiestner
Journal:  Nat Rev Cancer       Date:  2018-01-19       Impact factor: 60.716

Review 9.  The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.

Authors:  Haoran Wang; Wentao Zhang; Jingyi Yang; Keshu Zhou
Journal:  Hematol Oncol       Date:  2021-10-15       Impact factor: 4.850

Review 10.  New roles for B cell receptor associated kinases: when the B cell is not the target.

Authors:  Phuong-Hien Nguyen; Emanuel Niesen; Michael Hallek
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.